

## Fycompa<sup>®</sup> (perampanel) – First-time generic

- On May 29, 2025, [Teva launched](#) an [AB-rated](#) generic version of Catalyst's [Fycompa \(perampanel\)](#) tablets.
  - Fycompa is a Schedule III controlled substance.
- Fycompa is approved:
  - For the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older
  - As adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
- Fycompa is also available as a brand oral suspension that carries the same indications as Fycompa tablets.
- Fycompa carries a boxed warning for serious psychiatric and behavioral reactions.

